Biochemical and physical function outcomes in adults with pediatric-onset hypophosphatasia treated with asfotase alfa for up to 3 years: interim results from a Phase 2 study
Publication
, Conference
Kishnani, P; Gayron, M; Denker, AE; Watsky, E; Rockman-Greenberg, CR
Published in: CLINICAL ENDOCRINOLOGY
January 1, 2017
Duke Scholars
Published In
CLINICAL ENDOCRINOLOGY
EISSN
1365-2265
ISSN
0300-0664
Publication Date
January 1, 2017
Volume
86
Start / End Page
66 / 66
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Endocrinology & Metabolism
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kishnani, P., Gayron, M., Denker, A. E., Watsky, E., & Rockman-Greenberg, C. R. (2017). Biochemical and physical function outcomes in adults with pediatric-onset hypophosphatasia treated with asfotase alfa for up to 3 years: interim results from a Phase 2 study. In CLINICAL ENDOCRINOLOGY (Vol. 86, pp. 66–66). WILEY-BLACKWELL.
Kishnani, Priya, Marisa Gayron, Andrew E. Denker, Eric Watsky, and Cheryl R. Rockman-Greenberg. “Biochemical and physical function outcomes in adults with pediatric-onset hypophosphatasia treated with asfotase alfa for up to 3 years: interim results from a Phase 2 study.” In CLINICAL ENDOCRINOLOGY, 86:66–66. WILEY-BLACKWELL, 2017.
Kishnani P, Gayron M, Denker AE, Watsky E, Rockman-Greenberg CR. Biochemical and physical function outcomes in adults with pediatric-onset hypophosphatasia treated with asfotase alfa for up to 3 years: interim results from a Phase 2 study. In: CLINICAL ENDOCRINOLOGY. WILEY-BLACKWELL; 2017. p. 66–66.
Kishnani, Priya, et al. “Biochemical and physical function outcomes in adults with pediatric-onset hypophosphatasia treated with asfotase alfa for up to 3 years: interim results from a Phase 2 study.” CLINICAL ENDOCRINOLOGY, vol. 86, WILEY-BLACKWELL, 2017, pp. 66–66.
Kishnani P, Gayron M, Denker AE, Watsky E, Rockman-Greenberg CR. Biochemical and physical function outcomes in adults with pediatric-onset hypophosphatasia treated with asfotase alfa for up to 3 years: interim results from a Phase 2 study. CLINICAL ENDOCRINOLOGY. WILEY-BLACKWELL; 2017. p. 66–66.
Published In
CLINICAL ENDOCRINOLOGY
EISSN
1365-2265
ISSN
0300-0664
Publication Date
January 1, 2017
Volume
86
Start / End Page
66 / 66
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Endocrinology & Metabolism
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences